Global Hemophilia Treatment Market Report to 2027 – Players include Medexus Pharmaceuticals, Novo Nordisk, Octapharma and Pfizer –


DUBLIN–(BUSINESS WIRE)–The “Hemophilia Treatment Market – Global Industry Analysis (2019-2021) – Market Growth Trends and Forecast (2022-2027)” report has been added to’s offer.

Worldwide, the incidence of hemophilia has been on the rise in recent years. Classified as a rare disease, hemophilia occurs due to the absence or lack of a protein known as clotting factor. It is divided into three main types, namely haemophilia A, haemophilia B and acquired haemophilia.

Due to the increasing incidence of hemophilia and the increasing prevalence of blood clotting diseases in the adult population, healthcare professionals (HCPs) are strongly motivated to develop new therapies to treat the haemophilia.

This trend is extremely viable for the global hemophilia treatment market as it has opened strong business opportunities for manufacturers in international markets. In the near future, innovation in hemophilia treatments, development of new procedures and strong hemophilia awareness programs are poised to strengthen the global hemophilia treatment market, enabling it to grow. reach a total market value of US$21,349 million by 2027.

Key insights and trends in the global hemophilia treatment market

Between 2022 and 2027, the global Hemophilia Treatment Market will grow at a promising CAGR of 5.2% thanks to healthy market competition, aggressive pursuit of new therapies, strategic partnerships among market players and strong government rebates.

Based on applications, the prophylaxis segment is poised to register the highest growth, reaching a total market valuation of US$8 billion by 2027.

Whereas, based on the type of treatment, the recombinant factor concentrates segment is expected to contribute almost 40% in terms of value.

Over the forecast period, in terms of type of treatment indication, Hemophilia B is expected to register a robust CAGR of around 6%, while Hemophilia A is expected to lead in terms of total value generated, which is expected to be around US$15 billion. .

Favorable prospects towards new therapies should open up new revenue streams

Several advanced hemophilia treatment options have surfaced in recent years, and several more are in the final stages of clinical trials. New therapies, namely extended half-life factor concentrates (FVIII/FIX), gene therapy for hemophilia, targeting of natural anticoagulant pathways and biphasic antibodies, together with new clotting factor concentrates ( CFC), have significantly reduced the burden of patient care. Consequently, the demand for new hemophilia treatments has increased dramatically.

However, concerns over treatment efficacy and overall cost are expected to limit the rapid market growth in the coming years – a challenge that is being overcome through government rebates and rigorous R&D initiatives by public and private entities. .

North America maintains market leadership position

North America continues to hold the highest market share in the global hemophilia treatment market. It recorded a total market value of US$6,481 million in 2022, and by 2027, this market value is expected to reach US$7,899 million, growing at a CAGR of 4.0%.

In North America, major factors that are harnessing the growth of the global hemophilia treatment market include the presence of key industry players, government rebates, and higher national income. Additionally, the availability of modern treatments at relatively lower prices is expected to see Asia Pacific record a robust CAGR of 7.2% over the assessment period.

Companies cited

  • Bayer AG

  • BioMarin Pharmaceuticals, Inc.

  • F. Hoffman La Roche Ltd.

  • Grifols SA

  • Sanofi

  • Takeda Pharmaceuticals Company Ltd.

  • CSL Behring

  • Medexus Pharmaceuticals Inc.

  • Novo Nordisk

  • Octapharma AG

  • Pfizer Inc.

Main topics covered:

1. Summary

2. Market Overview

2.1. Market definitions and segmentations

2.2. Market dynamics

2.2.1. Market factors

2.2.2. Market threats

2.2.3. Market opportunities

2.3. Regulatory framework

2.4. Clinical Scenario Value Framework

2.5. Hemophilia Treatment Centres: Comprehensive Care Model

2.6. Refund scenario

2.7. COVID 19 impact analysis

2.8. Hemophilia market landscape

3. Global Hemophilia Treatment Market Outlook, 2019- 2027

4. North America Hemophilia Treatment Market Outlook, 2019- 2027

5. Europe Hemophilia Treatment Market Outlook, 2019- 2027

6. Asia-Pacific Hemophilia Treatment Market Outlook, 2019- 2027

7. Rest of the World Hemophilia Treatment Market Outlook, 2019- 2027

8. Competitive Landscape

8.1. Market share analysis, 2021

8.2. Company Profiles

9. Appendix

For more information on this report, visit


Comments are closed.